Eledon Pharmaceuticals (ELDN) Financials

Eledon Pharmaceuticals (NASDAQ: ELDN) remains a development-stage biotech with no reported revenue, so the story is still centered on cash, spending, and balance-sheet strength rather than operating sales. The latest quarter shows the company continues to burn cash, but it also maintains a large investment portfolio that gives it a meaningful liquidity cushion.

For Q1 2026, Eledon reported:

• $113.6 million in current assets, including $6.2 million in cash and equivalents and $104.9 million in short-term investments.
• $146.7 million in total assets versus $46.2 million in total liabilities, giving the company a substantial asset base.
• $44.8 million in total equity, indicating the balance sheet still has a positive equity position.
• No revenue in the quarter, which is common for clinical-stage biotech but means the company is still fully dependent on financing and investment income.
• Operating expenses were $21.2 million, with R&D at $17.2 million and SG&A at $4.0 million.
• Net loss was $39.0 million, reflecting both operating losses and a large negative other-income/expense line of $17.8 million.
• Operating cash burn was $22.6 million for the quarter.
• Investing activities generated $6.0 million in net cash, as sales and maturities of investments exceeded new purchases.
• Cash and equivalents fell to $6.2 million from $3.7 million at Q3 2025 and $8.5 million at Q1 2025, showing that most liquidity is tied up in investments rather than cash.
• Retained earnings remain deeply negative at $(440.2) million, underscoring the company’s long history of cumulative losses.

What stands out over the last four years is the rapid expansion in assets funded by equity issuance and investment activity. Eledon’s cash and investment holdings grew dramatically from early 2024 to late 2025, largely because of financing transactions, including large common-equity issuance in prior periods. That helped offset ongoing operating losses and kept the company well capitalized for now.

At the same time, the underlying business trend remains unchanged: no revenue, persistent operating losses, and significant quarterly cash burn. R&D spending remains the largest expense category, which suggests management is still prioritizing pipeline development. That can be positive if the clinical program progresses, but it also means investors should expect continued losses until commercialization or a strategic partnership changes the profile.

Bottom line: Eledon currently looks financially stable enough to keep operating near term, thanks to its investment balance and overall asset position. However, it is still a cash-burning biotech with no sales, so the stock remains highly dependent on clinical execution and future financing needs.